Insulin, thrombin, ERK1/2 kinase and vascular smooth muscle cells proliferation

Current Pharmaceutical Design

Volumn 16, Issue 35, 2010, Pages 3895-3902

  Isenović, Esma R ^a   Soskić, Sanja ^a   Trpković, Andreja ^b   Dobutović, Branislava ^a   Popović, Milan ^a   Gluvić, Zoran ^b   Putniković, Biljana ^b   Marche, Pierre ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Hospital Center Zemun   (Serbia)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Akt; ERK1 2; INS; Proliferation; Thrombin; VSMC

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOTENSINOGEN; CYCLIC AMP; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PLATELET DERIVED GROWTH FACTOR AB; PROLINE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P21; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SERINE; THREONINE; THROMBIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNINDEXED DRUG; WORTMANNIN;

ARTERY DILATATION; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; EUKARYOTIC CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ARTICLE; CYTOLOGY; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN; MUSCLE, SMOOTH, VASCULAR; THROMBIN;

EID: 79551645602     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454987     Document Type: Review

References (101)

1. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75(3): 487-517.
2. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84(3): 767-801.
3. Sobue K, Hayashi K, Nishida W. Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation. Mol Cell Biochem 1999; 190(1-2): 105-18.
4. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 2007; 45 (Suppl A): A25-32.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362(6423): 801-9.
6. Campbell JH, Black MJ, Campbell GR. Replication of smooth muscle cells in atherosclerosis and hypertension. New York: Raven Press 1989.
7. Colwell JA, Lyons TJ, Klein RL, Lopes-Virella M. New concepts about the pathogenesis of atherosclerosis and thrombosis in diabetes mellitus. St. Louis: Mosby 1992.
8. Colwell JA, Jokl R. Vascular thrombosis in diabetes. Norwalk: Appleton and Lange 1996.
9. Stout RW. Insulin and atherogenesis. Eur J Epidemiol 1992; 8 (Suppl 1): 134-5.
10. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, 2nd, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91(1): 94-8.
11. Hsieh HL, Tung WH, Wu CY, et al. Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Srcdependent pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009; 29(10): 1594-601.
12. Schauwienold D, Plum C, Helbing T, et al. ERK1/2-dependent contractile protein expression in vascular smooth muscle cells. Hypertension 2003; 41(3): 546-52.
13. Schwartz SM, Ross R. Cellular proliferation in atherosclerosis and hypertension. Prog Cardiovasc Dis 1984; 26(5): 355-72.
14. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976; 295(8): 420-5.
15. Aikawa M, Sakomura Y, Ueda M, et al. Redifferentiation of smooth muscle cells after coronary angioplasty determined via myosin heavy chain expression. Circulation 1997; 96(1): 82-90.
16. Reusch HP, Schaefer M, Plum C, Schultz G, Paul M. Gbeta gamma mediate differentiation of vascular smooth muscle cells. J Biol Chem 2001; 276(22): 19540-7.
17. Stepien O, Zhang Y, Zhu D, Marche P. Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 2002; 20(1): 95-102.
18. Whitmarsh AJ, Davis RJ. A central control for cell growth. Nature 2000; 403(6767): 255-6.
19. Mogami H, Kojima I. Stimulation of calcium entry is prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 196(2): 650-8.
20. Short AD, Bian J, Ghosh TK, Waldron RT, Rybak SL, Gill DL. Intracellular Ca2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA 1993; 90(11): 4986-90.
21. Zhang YZ, Gao PJ, Wang XY, et al. The inhibitory mechanisms of amlodipine in human vascular smooth muscle cell proliferation. Hypertens Res 2000; 23(4): 403-6.
22. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension 1992; 20(6): 713-36.
23. Stepien O, Gogusev J, Zhu DL, et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31(5): 786-93.
24. Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 1989; 80(1): 17-26.
25. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82(6): 1940-53.
26. Isenovic ER, Fretaud M, Koricanac G, et al. Insulin regulation of proliferation involves activation of AKT and ERK 1/2 signalling pathways in vascular smooth muscle cells. Exp Clin Endocrinol Diabetes 2009; 117(5): 214-9.
27. Munaron L, Antoniotti S, Distasi C, Lovisolo D. Arachidonic acid mediates calcium influx induced by basic fibroblast growth factor in Balb-c 3T3 fibroblasts. Cell Calcium 1997; 22(3): 179-88.
28. Berk BC, Taubman MB, Cragoe EJ, Jr., Fenton JW, 2nd, Griendling KK. Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase Cdependent and -independent pathways. J Biol Chem 1990; 265(28): 17334-40.
29. Fager G. Thrombin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77(4): 645-50.
30. Hughes AD. Calcium channels in vascular smooth muscle cells. J Vasc Res 1995; 32(6): 353-70.
31. Chao TS, Byron KL, Lee KM, Villereal M, Rosner MR. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor. J Biol Chem 1992; 267(28): 19876-83.
32. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31(1 Pt 2): 152-61.
33. Miyamoto T, Leconte I, Swain JL, Fox JC. Autocrine FGF signalling is required for vascular smooth muscle cell survival in vitro. J Cell Physiol 1998; 177(1): 58-67.
34. Mii S, Khalil RA, Morgan KG, Ware JA, Kent KC. Mitogenactivated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 1996; 270(1 Pt 2): H142-50.
35. Seewald S, Seul C, Kettenhofen R, et al. Role of mitogen-activated protein kinase in the angiotensin II-induced DNA synthesis in vascular smooth muscle cells. Hypertension 1998; 31(5): 1151-6.
36. Huang J, Mohammadi M, Rodrigues GA, Schlessinger J. Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. J Biol Chem 1995; 270(10): 5065-72.
37. Bobe R, Yin X, Roussanne MC, et al. Evidence for ERK1/2 activation by thrombin that is independent of EGFR transactivation. Am J Physiol Heart Circ Physiol 2003; 285(2): H745-54.
38. Burkhard K, Smith S, Deshmukh R, MacKerell AD, Jr., Shapiro P. Development of extracellular signal-regulated kinase inhibitors. Curr Top Med Chem 2009; 9(8): 678-89.
39. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
40. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007; 50(3): 409-24.
41. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signalling. Int J Biochem Cell Biol 2009; 41(12): 2351-5.
42. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signalling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000; 19(23): 6341-50.
43. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004; 110(6): 718-23.
44. Zhai P, Gao S, Holle E, et al. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem 2007; 282(45): 33181-91.
45. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28(5): 463-91.
46. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-904.
47. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 1997; 417(3): 283-6.
48. Schulman IH, Zhou MS. Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep 2009; 11(1): 48-55.
49. Wang CC, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signalling pathways. Diabetes 2003; 52(10): 2562-9.
50. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signalling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100(9): 2158-69.
51. Chen XL, Chen ZS, Ding Z, Dong C, Guo H, Gong NQ. Antisense extracellular signal-regulated kinase-2 gene therapy inhibits platelet-derived growth factor-induced proliferation, migration and transforming growth factor-beta(1) expression in vascular smooth muscle cells and attenuates transplant vasculopathy. Transpl Int 2008; 21(1): 30-8.
52. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004; 22(1): 121-7.
53. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004; 22(9): 1779-85.
54. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5(12): 1359-64.
55. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27(1): 27-36.
56. Muramatsu I, Laniyonu A, Moore GJ, Hollenberg MD. Vascular actions of thrombin receptor peptide. Can J Physiol Pharmacol 1992; 70(7): 996-1003.
57. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol 1993; 22(4): 609-16.
58. Tesfamariam B. Thrombin receptor-mediated vascular relaxation differentiated by a receptor antagonist and desensitization. Am J Physiol 1994; 267(5 Pt 2): H1962-7.
59. Tesfamariam B. Distinct receptors and signalling pathways in alpha-thrombin- and thrombin receptor peptide-induced vascular contractions. Circ Res 1994; 74(5): 930-6.
60. Ku DD, Dai J. Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. J Cardiovasc Pharmacol 1997; 30(5): 649-57.
61. Mizuno O, Hirano K, Nishimura J, Kubo C, Kanaide H. Mechanism of endothelium-dependent relaxation induced by thrombin in the pig coronary artery. Eur J Pharmacol 1998; 351(1): 67-77.
62. Derkach DN, Ihara E, Hirano K, Nishimura J, Takahashi S, Kanaide H. Thrombin causes endothelium-dependent biphasic regulation of vascular tone in the porcine renal interlobar artery. Br J Pharmacol 2000; 131(8): 1635-42.
63. Watts VL, Motley ED. Role of protease-activated receptor-1 in endothelial nitric oxide synthase-Thr495 phosphorylation. Exp Biol Med (Maywood) 2009; 234(2): 132-9.
64. Mizuno O, Hirano K, Nishimura J, Kubo C, Kanaide H. Proteolysis and phosphorylation-mediated regulation of thrombin receptor activity in in situ endothelial cells. Eur J Pharmacol 2000; 389(1): 13-23.
65. Godin D, Rioux F, Marceau F, Drapeau G. Mode of action of thrombin in the rabbit aorta. Br J Pharmacol 1995; 115(6): 903-8.
66. Soifer SJ, Peters KG, O'Keefe J, Coughlin SR. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 1994; 144(1): 60-9.
67. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90(4): 1614-21.
68. Wilcox JN, Rodriguez J, Subramanian R, et al. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75(6): 1029-38.
69. Hirano K, Yufu T, Hirano M, Nishimura J, Kanaide H. Physiology and pathophysiology of proteinase-activated receptors (PARs): regulation of the expression of PARs. J Pharmacol Sci 2005; 97(1): 31-7.
70. Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P. Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost 1999; 81(5): 808-14.
71. Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. Circulation 1997; 96(11): 3888-96.
72. Papadaki M, Ruef J, Nguyen KT, et al. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. Circ Res 1998; 83(10): 1027-34.
73. Hung DT, Wong YH, Vu TK, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 1992; 267(29): 20831-4.
74. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91(2): 504-8.
75. Barr AJ, Brass LF, Manning DR. Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor.G protein coupling. J Biol Chem 1997; 272(4): 2223-9.
76. Kozasa T, Jiang X, Hart MJ, et al. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 1998; 280(5372): 2109-11.
77. Hart MJ, Jiang X, Kozasa T, et al. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. Science 1998; 280(5372): 2112-4.
78. Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J Biol Chem 1999; 274(9): 5868-79.
79. Offermanns S, Mancino V, Revel JP, Simon MI. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997; 275(5299): 533-6.
80. Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell 1998; 9(9): 2639-53.
81. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144(4): 745-54.
82. Taylor SJ, Chae HZ, Rhee SG, Exton JH. Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 1991; 350(6318): 516-8.
83. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389(6647): 183-6.
84. Stoyanov B, Volinia S, Hanck T, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995; 269(5224): 690-3.
85. Clapham DE, Neer EJ. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 1997; 37: 167-203.
86. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999; 11(2): 219-25.
87. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402(6764): 884-8.
88. Zwick E, Wallasch C, Daub H, Ullrich A. Distinct calciumdependent pathways of epidermal growth factor receptor transactivation and PYK2 tyrosine phosphorylation in PC12 cells. J Biol Chem 1999; 274(30): 20989-96.
89. Wang H, Ubl JJ, Stricker R, Reiser G. Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signalling pathways. Am J Physiol Cell Physiol 2002; 283(5): C1351-64.
90. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276(11): 7957-62.
91. Ginnan R, Singer HA. CaM kinase II-dependent activation of tyrosine kinases and ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 2002; 282(4): C754-61.
92. Chen YH, Pouyssegur J, Courtneidge SA, Van Obberghen-Schilling E. Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. J Biol Chem 1994; 269(44): 27372-7.
93. Schieffer B, Drexler H, Ling BN, Marrero MB. G protein-coupled receptors control vascular smooth muscle cell proliferation via pp60c-src and p21ras. Am J Physiol 1997; 272(6 Pt 1): C2019-30.
94. Vaingankar SM, Martins-Green M. Thrombin aivation of the 9E3/CEF4 chemokine involves tyrosine kinases including c-src and the epidermal growth factor receptor. J Biol Chem 1998; 273(9): 5226-34.
95. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996; 383(6600): 547-50.
96. Blaukat A, Ivankovic-Dikic I, Gronroos E, et al. Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogenactivated protein kinase cascades. J Biol Chem 1999; 274(21): 14893-901.
97. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 1998; 17(11 Reviews): 1331-42.
98. Kanda Y, Mizuno K, Kuroki Y, Watanabe Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 2001; 132(8): 1657-64.
99. Isenovic ER, Trpkovic A, Zakula Z, Koricanac G, Marche P. Role of ERK1/2 Activation In Thrombin-Induced Vascular Smooth Muscle Cell Hypertrophy. Curr Hypertens Rev 2008; 4: 190-6.
100. Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 1998; 82(1): 7-12.
101. Touyz RM, Wu XH, He G, et al. Role of c-Src in the regulation of vascular contraction and Ca2+ signalling by angiotensin II in human vascular smooth muscle cells. J Hypertens 2001; 19(3): 441-9.